Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF
Recruiting · NCT04603404 · Observational (researchers observe without assigning treatment) · Lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
View the official record on ClinicalTrials.gov →What this trial is about
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modal (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF derived from different causes.
Who can take part
Inclusion criteria
- left ventricular ejection fraction (LVEF)≥50%；
- N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml;
- symptoms and syndromes of heart failure;
- At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).
Exclusion criteria
- Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc.
- Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ;
- Severe arrhythmia;
- Severe primary cardiac valvular disease;
- Restrictive pericardial disease;
- Refuse to participate in the study.
Where it is running
1 location listed.
- Fuwai Hospital - Beijing, Beijing Municipality, China